IQVIA (NYSE:IQV) Downgraded by StockNews.com

IQVIA (NYSE:IQVGet Rating) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday.

Several other research firms have also issued reports on IQV. Mizuho dropped their price target on IQVIA from $300.00 to $270.00 and set a “buy” rating on the stock in a research report on Monday, March 7th. Wells Fargo & Company lowered IQVIA from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $290.00 to $235.00 in a research report on Monday. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research report on Wednesday, February 16th. UBS Group dropped their target price on IQVIA from $310.00 to $290.00 in a research report on Wednesday, February 16th. Finally, Piper Sandler dropped their target price on IQVIA from $261.00 to $231.00 and set a “neutral” rating on the stock in a research report on Thursday, February 17th. Four investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $278.53.

Shares of IQV stock traded down $13.13 on Tuesday, hitting $206.73. 2,113,281 shares of the stock traded hands, compared to its average volume of 1,132,116. The company has a debt-to-equity ratio of 1.99, a current ratio of 0.91 and a quick ratio of 0.91. The company has a market capitalization of $39.47 billion, a PE ratio of 41.68, a PEG ratio of 2.02 and a beta of 1.46. IQVIA has a 1-year low of $205.03 and a 1-year high of $285.61. The company’s fifty day moving average is $229.16 and its 200 day moving average is $247.24.

IQVIA (NYSE:IQVGet Rating) last posted its quarterly earnings results on Tuesday, February 15th. The medical research company reported $2.42 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.25 by $0.17. The business had revenue of $3.64 billion for the quarter, compared to analyst estimates of $3.61 billion. IQVIA had a return on equity of 27.51% and a net margin of 6.96%. The business’s revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the company posted $2.00 EPS. As a group, equities research analysts expect that IQVIA will post 9.43 EPS for the current year.

A number of hedge funds have recently made changes to their positions in the stock. RE Advisers Corp boosted its stake in IQVIA by 30.5% during the fourth quarter. RE Advisers Corp now owns 184 shares of the medical research company’s stock valued at $52,000 after buying an additional 43 shares in the last quarter. Horizon Investments LLC boosted its stake in IQVIA by 3.3% during the third quarter. Horizon Investments LLC now owns 1,418 shares of the medical research company’s stock valued at $340,000 after buying an additional 45 shares in the last quarter. FDx Advisors Inc. boosted its position in shares of IQVIA by 0.8% in the 4th quarter. FDx Advisors Inc. now owns 6,382 shares of the medical research company’s stock valued at $1,801,000 after purchasing an additional 49 shares during the period. Vestmark Advisory Solutions Inc. boosted its position in shares of IQVIA by 5.8% in the 4th quarter. Vestmark Advisory Solutions Inc. now owns 892 shares of the medical research company’s stock valued at $252,000 after purchasing an additional 49 shares during the period. Finally, Enterprise Financial Services Corp boosted its position in shares of IQVIA by 4.2% in the 4th quarter. Enterprise Financial Services Corp now owns 1,230 shares of the medical research company’s stock valued at $347,000 after purchasing an additional 50 shares during the period. 86.66% of the stock is owned by institutional investors and hedge funds.

About IQVIA (Get Rating)

IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Read More

Analyst Recommendations for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.